Lupin today announced that it has received tentative approval from the United States Food and Drug Administration (FDA) for its
Abbreviated New Drug Application (ANDA) Ivacaftor Tablets, 150 mg, to market a generic equivalent of Kalydeco Tablets, 150 mg of Vertex Pharmaceuticals Incorporated. This product will be manufactured at
Lupin's Nagpur facility in India.
Ivacaftor Tablets (RLD: Kalydeco Tablets) had estimated annual sales of USD 109 million in the U.S. (IQVIA MAT March 2022).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
